Format

Send to

Choose Destination
Am J Respir Crit Care Med. 2018 Aug 22. doi: 10.1164/rccm.201803-0575OC. [Epub ahead of print]

Rhinovirus Species-Specific Antibodies Differentially Reflect Clinical Outcomes in Health and Asthma.

Author information

1
University of Manchester, Division of Infection, Immunity and Respiratory Medicine, Manchester, United Kingdom of Great Britain and Northern Ireland.
2
Medical University of Vienna, Division of Immunopathology, Department of Pathophysiology and Allergy Research, Vienna, Austria.
3
National and Kapodistrian University of Athens, 68993, Athinon, Greece.
4
Medical University, Immunology ,Rheumatology and Allergy, Lodz, Poland.
5
Turun Yliopisto, 8058, Department of Paediatrics, Turku, Finland.
6
Universiteit Gent, 26656, Upper Airways Research Laboratory, Gent, Belgium.
7
Institute of molecular pneumology, erlangen, Germany.
8
University of Manchester, Centre for Respiratory Medicine & Allergy, Manchester, United Kingdom of Great Britain and Northern Ireland.
9
Athens General Children's Hospital "Pan. & Aglaia Kyriakou", Athens, Greece.
10
Medical University of Lodz, Department of Rheumatology, Lodz, Poland.
11
Turun Yliopisto, 8058, Department of Paediatrics Turku University Hospital , Turku, Finland.
12
Upper airway Research lab, Otorhinolaryngology, Gent, Belgium.
13
University of Erlangen, Children Hospital, Erlangen, Germany.
14
Biomay AG
, Vienna, Austria.
15
University of Zurich, Swiss Institute of Allergy and Asthma Research, Zurich, Switzerland.
16
Biomedical Research Foundation Academy of Athens, Center for Immunology and Transplantation, Athens, Greece.
17
Imperial College London, Kennedy Institute of Rheumatology, London, United Kingdom of Great Britain and Northern Ireland.
18
Medical University of Vienna, Christian Doppler Laboratory for Allergy Research, Vienna, Austria.
19
University of Manchester, 5292, Institute of Human Development, Manchester, Greater Manchester, United Kingdom of Great Britain and Northern Ireland ; nikolaos.papadopoulos@manchester.ac.uk.

Abstract

RATIONALE:

Rhinoviruses are major triggers of common cold and acute asthma exacerbations; Rhinovirus species A, B and C may have distinct clinical impact; however, little is known regarding RV species-specific antibody responses in health and asthma.

OBJECTIVES:

To describe and compare total and rhinovirus species-specific antibody levels in healthy and asthmatic children, away from an acute event.

METHODS:

Serum samples from 163 preschool children with mild to moderate asthma and 72 healthy controls from the multinational Predicta cohort were analysed using the recently developed PreDicta rhinovirus antibody chip.

MAIN RESULTS:

Rhinovirus antibody levels varied, with rhinovirus C and rhinovirus A being higher than rhinovirus B in both groups. Compared to controls, asthma was characterised by significantly higher levels of antibodies to rhinovirus A and rhinovirus C, but not rhinovirus B. Rhinovirus antibody levels positively correlated with the number of common colds over the previous year in healthy children, and wheeze episodes in asthmatics. Antibody levels also positively correlated with asthma severity but not with current asthma control.

CONCLUSIONS:

The variable humoral response to rhinovirus species in both groups, suggests a differential infectivity pattern between rhinovirus species. In healthy pre-schoolers, rhinovirus antibodies accumulate with colds. In asthma, rhinovirus A and rhinovirus C antibodies are much higher and further increase with disease severity and wheeze episodes. Higher antibody levels in asthma may be due to a compromised innate immune response, leading to increased exposure of the adaptive immunity to the virus. Importantly, there is no apparent protection with increasing levels of antibodies.

KEYWORDS:

Antibody; Asthma; Chip; Predicta; Rhinovirus

PMID:
30134114
DOI:
10.1164/rccm.201803-0575OC

Supplemental Content

Full text links

Icon for Atypon
Loading ...
Support Center